Matrine 苦参碱; Matridin-15-one; Vegard; α-Matrine|cas:519-02-8|西域试剂

Matrine 苦参碱; Matridin-15-one; Vegard; α-Matrine,98.0%

产品编号：Bellancom-N0164| CAS NO：519-02-8| 分子式：C₁₅H₂₄N₂O| 分子量：248.36

Matrine (Matridin-15-one) 是一种在槐属植物中发现的生物碱，可作为 kappa 阿片受体和 u-受体激动剂。Matrine 具有多种药理作用，包括抗癌、抗氧化应激、抗炎和抗凋亡作用，可用于人类非小细胞肺癌、肝癌、甲状腺乳头状癌和急性肾损伤 (AKI) 等疾病的研究。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-N0164	￥976.00	杭州北京（现货）
Bellancom-N0164	￥1674.00	杭州北京（现货）
Bellancom-N0164	￥2976.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Matrine 苦参碱; Matridin-15-one; Vegard; α-Matrine

产品介绍

Matrine (Matridin-15-one) 是一种在槐属植物中发现的生物碱，可作为 kappa 阿片受体和 u-受体激动剂。Matrine 具有多种药理作用，包括抗癌、抗氧化应激、抗炎和抗凋亡作用，可用于人类非小细胞肺癌、肝癌、甲状腺乳头状癌和急性肾损伤 (AKI) 等疾病的研究。

生物活性

Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)^[4]^[5].

体外研究

Matrine (0-1.5 mg/mL, 24-72 h) inhibits the growth of A549 and SMMC-7721 cells.
Matrine (25 μg/mL, 6 h) suppresses migration of A549 cells.
Matrine (0-1 mg/mL, 48 h) induces apoptosis by reducing the Bcl-2/Bax protein ratios in A549 and SMMC-7721 cells.
Matrine (0-1 mg/mL, 48 h) inhibits miR-182-5p expression and induces the apoptosis of PTC cells.
Matrine (10 μM, 48 h) inhibits cisplatin-induced oxidative injury and inflammation in HK2 cells by reducing ROS level and pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α^[4].
Matrine (10 μM, 48 h) reverses mitochondrial function in cisplatin-induced HK2 cells by activating the SIRT3/OPA1 pathway^[4].
Matrine (0-20 nM, 12 h) promotes HepG2 cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	A549, SMMC-7721 cells
Concentration:	0-500 μg/mL for A549 cells, 0-1.5 mg/mL for SMMC-7721 cells
Incubation Time:	24-72 h
Result:	Inhibited the growth of A549 and SMMC-7721 cells.

Western Blot Analysis

Cell Line:	A549, SMMC-7721 cells
Concentration:	100-250 μg/mL for A549 cells, 0.5-1 mg/mL for SMMC-7721 cells
Incubation Time:	24 h
Result:	Down-regulated the expression of anti-apoptotic protein (Bcl-2) and up-regulated the level of pro-apoptotic protein (bax).

Immunofluorescence^[4]

Cell Line:	HK2 cells
Concentration:	10 μM
Incubation Time:	48 h
Result:	Increased SIRT3 expression reduced under cisplatin stimuli.

体内研究
(In Vivo)

Matrine (Intragastric administration, 40 and 80 mg/kg for 16 consecutive days, xenograft male C57BL/6mice model) inhibits tumors growth and metastasis without affecting the body weight.
Matrine (Intraperitoneal injections, 5 mg/kg, daily for four continuous days) attenuates renal injury and apoptosis in cisplatin-induced AKI mice, as well as reducing inflammatory responses and activating SIRT3/OPA1 axis and rescues renal mitochondrial dysfunction^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft male C57BL/6mice model (LLC cells)
Dosage:	40 and 80 mg/kg for 16 consecutive days
Administration:	Intragastric administration
Result:	Inhibited tumors growth. Decreased the ratio of CD206⁺/F4/80⁺, promoted the expression of CD4⁺ and CD8⁺ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.

Animal Model:	Cisplatin-induced acute kidney injury (AKI) mice model^[4]
Dosage:	5 mg/kg daily for 4 days
Administration:	Intraperitoneal injections
Result:	Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice. Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft male C57BL/6mice model (LLC cells)
Dosage:	40 and 80 mg/kg for 16 consecutive days
Administration:	Intragastric administration
Result:	Inhibited tumors growth. Decreased the ratio of CD206⁺/F4/80⁺, promoted the expression of CD4⁺ and CD8⁺ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.

Animal Model:	Cisplatin-induced acute kidney injury (AKI) mice model^[4]
Dosage:	5 mg/kg daily for 4 days
Administration:	Intraperitoneal injections
Result:	Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice. Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft male C57BL/6mice model (LLC cells)
Dosage:	40 and 80 mg/kg for 16 consecutive days
Administration:	Intragastric administration
Result:	Inhibited tumors growth. Decreased the ratio of CD206⁺/F4/80⁺, promoted the expression of CD4⁺ and CD8⁺ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.

Animal Model:	Cisplatin-induced acute kidney injury (AKI) mice model^[4]
Dosage:	5 mg/kg daily for 4 days
Administration:	Intraperitoneal injections
Result:	Attenuated tubular injury observed in AKI mice, including renal tubular necrosis,formation of tubular casts, cytoplasmic vacuoles and renal infiltrationof inflammatory cells in mice. Decreased serum levels of TNF-a and IL-6 and the phosphorylation of NF-κB, activated SIRT3/OPA1 axis and improved mitochondrial function.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (201.32 mM)

H₂O : 20 mg/mL (80.53 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0264 mL	20.1321 mL	40.2641 mL
5 mM	0.8053 mL	4.0264 mL	8.0528 mL
10 mM	0.4026 mL	2.0132 mL	4.0264 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 37.5 mg/mL (150.99 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.07 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.07 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (10.07 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (10.07 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Ying Zhang, et al. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 2009 Apr;59(3):191-200. [Content Brief]

. Songbo Fu, et al. Matrine induces papillary thyroid cancer cell apoptosis in vitro and suppresses tumor growth in vivo by downregulating miR-182-5p. Biomed Pharmacother. 2020 Aug;128:110327. [Content Brief]

. Bei Zhao, et al. Matrine suppresses lung cancer metastasis via targeting M2-like tumour-associated-macrophages polarization. Am J Cancer Res. 2021 Sep 15;11(9):4308-4328. [Content Brief]

[4]. Lu Yuan, et al. Matrine alleviates cisplatin‐induced acute kidney injury by inhibiting mitochondrial dysfunction and inflammation via SIRT3/OPA1 pathway. J Cell Mol Med v.26(13); 2022 Jul.

[5]. Runjie Wei, et al. Matrine promotes liver cancer cell apoptosis by inhibiting mitophagy and PINK1/Parkin pathways. Cell Stress Chaperones. 2018 Nov;23(6):1295-1309. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

危害码 (欧洲)	Xn: Harmful;
风险声明 (欧洲)	R20/21/22
安全声明 (欧洲)	22-26-36/37/39-45
海关编码	1302199001

1. 物质的识别

产品名：	Matrine
CAS号：	519-02-8
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Matrine
别名：	Matridin-15-one; Vegard; α-Matrine
分子式：
分子量：	248.36

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

26904-64-3

16837-52-8

519-02-8

文献：UNILEVER PLC; UNILEVER N.V.; HINDUSTAN UNILEVER LIMITED Patent: WO2009/109496 A1, 2009 ; Location in patent: Page/Page column 9-10 ;